Search

Acoramidis

[A264808] It was brought to market by BridgeBio Pharma and approved by the FDA in November 2024 to reduce negative cardiovascular outcomes in patients with cardiomyopathy caused by TTR amyloidosis. … [A264768] Although they share a mechanism of action, acoramidis is more selective for TTR and is a more potent stabilizer when compared to tafamidis.

Potassium acetate

Repaglinide

The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. … Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM).

Allopurinol

Allopurinol is a xanthine oxidase enzyme inhibitor that is considered to be one of the most effective drugs used to decrease urate levels and is frequently used in the treatment of chronic gout [A36705 … It was initially approved by the FDA in 1966 [L5674] and is now formulated by several manufacturers [L5677].

Ledipasvir

This is an important advantage relative to HCV drugs that target other viral enzymes such as the protease, for which rapid development of resistance has proven to be an important cause of therapeutic failure … Although its exact mechanism of action is unknown, it is postulated to prevent hyperphosphorylation of NS5A which is required for viral protein production.

Erdafitinib

[L5956, L5959] At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy … medicines tailoring to a patient's specific genetic mutation.

Sulfacetamide

An anti-infective agent that is used topically to treat skin infections and orally for urinary tract infections.

Golodirsen

Often, patients succumb to this condition by age 30 or younger due to cardiac and respiratory complications. … [L10773] Golodirsen was developed by Sarepta Therapeutics and granted accelerated FDA approval on December 12, 2019 due to the urgent need for this drug in patients suffering from a certain form of

Levamlodipine

[L1484] The names S-amlodipine and levamlodipine may be used interchangeably as both substances are the same, however. … [L10833] Levamlodipine belongs to the dihydropyridine group of calcium channel blockers.[L10833] This medication was first marketed in Russia and India before being granted FDA approval.

Desipramine

In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. … See toxicity section below for a complete listing of side effects.